Pfizer Weighing Options In Medical Technology Group Divestment
This article was originally published in The Gray Sheet
Schneider's rapid-exchange balloon catheter patent portfolio will be a key draw for firms considering whether to acquire the Pfizer unit, which has annual sales of $330 mil. On Feb. 26, the drug maker announced that it is "exploring strategic options" for divesting its $1.45 bil. medical technology group (MTG), which, in addition to Schneider, includes Howmedica ($880 mil.) and American Medical Systems ($90 mil.).
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.